BBOT insider trading
NasdaqGM HealthcareBridgeBio Oncology Therapeutics, Inc.: insider trade history from SEC Form 4 filings.
About BridgeBio Oncology Therapeutics, Inc.
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics targeting renin-angiotensin system and phosphoinositide 3-kinase malignancies. The company's product pipeline includes BBO-8520, a direct inhibitor targeting the on and off states of KRAS that is in Phase I clinical trial to treat patients with KRASG12C mutant non-small cell lung cancer; and BBO-10203, an orally bioavailable small molecule that is in Phase I clinical trial for treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS pancreatic ductal adenocarcinoma (PDAC), KRAS mutant colorectal cancer (CRC), and KRAS mutant NSCLC. It is also developing BBO-11818, an orally bioavailable pan KRAS on/off inhibitor that is in Phase I clinical trial to treat patients with KRASG12D and KRASG12V mutant NSCLC, PDAC, and CRC. The company was founded in 2016 is headquartered in South San Francisco, California.
Company website: bbotx.com
BBOT insider activity at a glance
FilingIQ tracks 32 insider transactions for BBOT in filings since Aug 11, 2025. The most recent transaction is dated Oct 1, 2026.
Across the full history, 0 open-market purchases
and 0 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
Latest BBOT Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
13F funds holding BBOT
Frequently asked
- How many insider trades does FilingIQ track for BBOT?
- FilingIQ tracks 32 Form 4 insider transactions for BBOT (BridgeBio Oncology Therapeutics, Inc.), covering filings from Aug 11, 2025 onwards. 6 of those are dated within the last 90 days.
- Are BBOT insiders net buyers or net sellers?
- Across the full Form 4 history for BBOT, 0 transactions (0%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does BBOT insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is BBOT in?
- BridgeBio Oncology Therapeutics, Inc. (BBOT) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $730.30M.
Methodology & sources
Every BBOT insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.